Musculoskeletal applications of GLP-1 RAs gained substantial momentum in 2024–2025, particularly for the management of osteoarthritis and sarcopenia, with systematic reviews identifying consistent signals supporting favorable structural, protective, immunomodulatory, and analgesic effects [166]. The gene discussed is GCG; the disease is osteoarthritis.